No clinical trials have been undertaken with this compound because of its structural complexity, low synthetic yield, and poor water solubility. Cematodin (LU-103793), a water-soluble analog of dolastatin 15, which has a terminal benzylamine moiety in place of dolapyrolidone, retains high cytotoxicity in vitro.